AstraZeneca plc (LON:AZN)‘s stock had its “overweight” rating reiterated by equities researchers at Barclays PLC in a report released on Monday. They presently have a GBX 6,000 ($75.52) price objective on the biopharmaceutical company’s stock. Barclays PLC’s price objective points to a potential upside of 31.41% from the stock’s previous close.
Other equities analysts have also issued reports about the company. BNP Paribas reaffirmed a “neutral” rating and set a GBX 5,300 ($66.71) target price on shares of AstraZeneca plc in a research report on Monday, April 3rd. Jefferies Group LLC lowered AstraZeneca plc from a “buy” rating to a “hold” rating and lowered their target price for the stock from GBX 5,350 ($67.34) to GBX 5,050 ($63.56) in a research report on Monday, April 10th. Shore Capital reaffirmed a “sell” rating on shares of AstraZeneca plc in a research report on Monday, March 27th. HSBC Holdings plc lowered AstraZeneca plc to a “reduce” rating and set a GBX 4,500 ($56.64) target price on the stock. in a research report on Friday, April 7th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of AstraZeneca plc in a research report on Wednesday, March 15th. Five equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of GBX 5,057.40 ($63.66).
AstraZeneca plc (LON:AZN) traded down 0.62% on Monday, reaching GBX 4566.00. 2,518,128 shares of the company traded hands. The stock’s market capitalization is GBX 57.77 billion. The firm has a 50 day moving average of GBX 4,808.85 and a 200-day moving average of GBX 4,576.87. AstraZeneca plc has a one year low of GBX 3,680.00 and a one year high of GBX 5,505.00.
TRADEMARK VIOLATION WARNING: This story was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.themarketsdaily.com/2017/04/13/astrazeneca-plc-azn-earns-overweight-rating-from-barclays-plc.html.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.